普通人群血液嗜酸性粒细胞计数:欧洲呼吸杂志%P 1901874 %X血液嗜酸性粒细胞计数在哮喘和慢性阻塞性肺病(COPD)等慢性呼吸系统疾病的治疗中越来越受到关注。尽管如此，一般人群中典型的血嗜酸性粒细胞水平，以及潜在的混杂因素对这些水平的影响还没有明确的定义。我们测量了从奥地利普通人群中随机抽取的11042名受试者的血嗜酸性粒细胞计数。然后我们:(1)确定了与高血嗜酸性粒细胞计数相关的因素(>75百分位);(2)排除具有这些因素的受试者，以估计“健康”亚群的中位血嗜酸性粒细胞计数(n=3641)。我们发现:(1)在整个群体,年龄≤18年(优势比2.41[或]),哮喘(或2.05)的风险,目前的吸烟(或1.72)的风险,积极皮肤针刺试验(或1.64),慢性阻塞性肺病(或1.56),代谢综合征(或1.41),男性性(或1.36)的风险和肥胖(或1.16)的风险显著(p < 0.05)与高血压相关的嗜酸性粒细胞计数(二进制多变量逻辑回归分析);并具有附加效应;(2)排除这些因素,那些年龄超过18年,血液中嗜酸性粒细胞计数是男性高于女性(平均120(5%,-95%置信区间CI: 30 - 330)和100(30 - 310)细胞·µL−1),随着年龄的增长并没有改变。成人中位血嗜酸性粒细胞计数明显低于目前认为的正常值，青春期后不随年龄变化，但受多种因素的显著影响，这些因素具有相加效应。这些观察将有助于在临床实践中对血嗜酸性粒细胞水平的解释。该手稿最近已被《欧洲呼吸杂志》接受发表。在我们的制作团队进行编辑和排版之前，它以公认的形式在这里出版。 After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: S. Hartl has received unrestricted research grants for the Ludwig Boltzmann Institute of COPD and Respiratory Epidemiology and is on advisory boards for GSK, Boehringer Ingelheim, Novartis, Menarini, Chiesi, AstraZeneca, MSD, Roche, Abbvie, Takeda and TEVA for respiratory oncology and COPD.Conflict of interest: M-K. Breyer reports unrestricted grants for the LEAD study from GlaxoSmithKline, Novartis Pharma, AstraZeneca, Chiesi Pharma, Menarini Pharma, TEVA Ratiopharm, MSD, Air Liquide Health Care, Pfizer Corporation, Boehringer Ingelheim and Mundipharma.Conflict of interest: O.C. Burghuber reports grants from Boehringer Ingelheim, GSK, AstraZeneca, Menarini, Teva, Pfizer, Chiesi, Federal State Goverment Dept of Health and Novartis, non-financial support from AirLiquid and Municipial Dept of Health in Vienna, during the conduct of the study; personal fees for advisory board work and lectures from Boehringer Ingelheim, AstraZeneca, Chiesi, MSD, Menarini and Roche, personal fees for advisory board work from GSK, outside the submitted work.Conflict of interest: A. Ofenheimer has nothing to disclose.Conflict of interest: A. Schrott has nothing to disclose.Conflict of interest: M.H. Urban reports grants from Nycomed Pharma, during the conduct of the study; personal fees for lectures and advisory board work from AstraZeneca and Boehringer Ingelheim, outside the submitted work.Conflict of interest: A. Agusti reports personal fees from AstraZeneca, Chiesi and Nuvaira, grants and personal fees from Menarini and GSK, outside the submitted work.Conflict of interest: M. Studnicka reports personal fees for consultancy from Chiesi, AstraZeneca, Novartis, Boehringer and Almirall, and personal fees for lectures from GSK, AstraZeneca, Almirall, Novartis and Boehringer, outside the submitted work.Conflict of interest: E.F.M. Wouters reports personal fees for advisory board work from Nycomed and Boehringer, grants from AstraZeneca and GSK, personal fees for lectures from AstraZeneca, Novartis, GSK and Chiesi, outside the submitted work.Conflict of interest: R. Breyer-Kohansal reports personal fees for presentations and/or participations for AstraZeneca, Boehringer Ingelheim, Chiesi and Novartis outside the submitted work. %U //www.qdcxjkg.com/content/erj/early/2020/01/24/13993003.01874-2019.full.pdf